Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-319 in SLE, SjD, and RA
NCT06977724Phase 1Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Aug 2025
- Primary completion
- Mar 2029
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label trial of ABBV-319 in systemic lupus erythematosus (SLE), Sjögren's syndrome and rheumatoid arthritis (RA) (8 arms), sponsored by AbbVie Inc. Primary endpoints: Number of Participants with Adverse Events, Change from Baseline in B Cells in Blood and Tissue and 6 more. Started Aug 2025; status: recruiting.
02
Drugs
ABBV-319
03
Conditions
systemic lupus erythematosus (SLE)Sjögren's syndromerheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT06977724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06977724.